Navigation Links
Amicus Therapeutics Announces Third Quarter 2008 Financial Results
Date:11/3/2008

Amicus Makes Steady Progress Toward Achievement of Milestones

CRANBURY, N.J., Nov. 3 /PRNewswire-FirstCall/ -- Amicus Therapeutics (Nasdaq: FOLD) today announced financial results for the third quarter of 2008. On a reported basis calculated in accordance with U.S. Generally Accepted Accounting Principles (GAAP), Amicus announced a net loss attributable to common stockholders of $0.36 per share ($0.29 per share on a non-GAAP basis) for the three months ended September 30, 2008. As of September 30, 2008, cash, cash equivalents, and marketable securities totaled $136.3 million.

"The third quarter of 2008 was another quarter of strong progress for Amicus as we focused on clinical and regulatory execution on our three lysosomal storage disease programs," said John F. Crowley, President and CEO of Amicus Therapeutics. "In recent months, we have continued the process with regulatory authorities in the United States and Europe in order to define the global development plan for Amigal(TM) in Fabry, and we remain on track to provide an update by the end of the year. In our Gaucher and Pompe disease programs, we continue to focus on advancing our ongoing Phase 2 clinical trials with the goal of reporting data in Gaucher in 2009. Finally, our financial position remains strong based on a healthy balance sheet and on the economics from our strategic alliance with Shire, which funds 50% of development costs for our lead programs in addition to success-based clinical and regulatory milestone payments."

Program Advancements

Fabry Disease:

Amigal (migalastat hydrochloride) is an investigational, oral therapeutic being developed for the treatment of Fabry disease. Amicus, along with its partner Shire Human Genetic Ther
'/>"/>

SOURCE Amicus Therapeutics
Copyright©2008 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6 7 8 9 10 11

Related biology technology :

1. Amicus Therapeutics Announces Third Quarter 2008 Results Release Date
2. Amicus Therapeutics to Present at the 2008 UBS Global Life Sciences Conference
3. Amicus Therapeutics Opens Research Facility in San Diego
4. Amicus Therapeutics to Present at the 2008 BioCentury NewsMakers in the Biotech Industry Conference
5. Amicus Therapeutics Announces Second Quarter 2008 Results Release Date
6. Amicus Therapeutics Announces First Quarter 2008 Financial Results
7. Amicus Therapeutics to Present at the Morgan Stanley Global Healthcare Unplugged Conference
8. Amicus Therapeutics Presents Positive Data from Phase 2 Clinical Trial of Plicera(TM) for Gaucher Disease
9. Amicus Therapeutics to Present at the BIO CEO & Investor Conference 2008
10. Amicus Therapeutics to Present at the Merrill Lynch Global Pharmaceutical, Biotechnology & Medical Device Conference
11. Amicus Therapeutics Announces Fourth Quarter and Full Year 2007 Financial Results & Program Advancements
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:7/31/2014)... Boston’s Adult Stem Cell Technology Center, LLC ... stem cell biotechnologies. Currently the company holds seven ... patent applications currently under examination by the U.S. Patent ... of the most vexing problems in adult stem cell ... are difficult to identify; and they have been difficult ...
(Date:7/30/2014)... 2014 Regulus Therapeutics Inc . (NASDAQ: ... discovery and development of innovative medicines targeting microRNAs, today ... for the quarter ended June 30, 2014 on Wednesday, ... Regulus will host a conference call ... pm Eastern Daylight Time to discuss its second quarter ...
(Date:7/30/2014)... 30, 2014 W. R. Grace ... of the REVELERIS® Prep purification system , ... chromatographers, and other researchers to perform both flash ... unit. , With the REVELERIS® Prep purification system, ... chromatography modes with a simple touch of the ...
(Date:7/30/2014)... 30, 2014 A study presented at ... and efficacy of CSL Behring,s C1 Inhibitor (C1-INH) ... in highly sensitized patients. C1-INH is a human ... system. The study shows that post-transplant ... the levels of complement components 3 and 4, ...
Breaking Biology Technology:The Adult Stem Cell Technology Center, LLC Launches A Marketing Campaign To License Adult Stem Cell Biotechnologies 2The Adult Stem Cell Technology Center, LLC Launches A Marketing Campaign To License Adult Stem Cell Biotechnologies 3Regulus Announces Timing for Second Quarter 2014 Financial Results Webcast and Conference Call 2Regulus Announces Timing for Second Quarter 2014 Financial Results Webcast and Conference Call 3Grace Launches New REVELERIS® Prep Purification System 2Study Suggests C1-INH May Aid in Prevention of Antibody-Mediated Rejection Following Kidney Transplant 2Study Suggests C1-INH May Aid in Prevention of Antibody-Mediated Rejection Following Kidney Transplant 3
... 3 BioMarin,Pharmaceutical Inc. (Nasdaq and SWX: BMRN) ... a program to develop an IgA protease for,treating ... cleave IgA,complexes, the deposition of which causes IgA ... BioMarin has executed a research,and option agreement with ...
... Vicus Therapeutics, LLC, an,oncology-focused, clinical-stage biopharmaceutical company, ... present at the BMO Capital,Markets Focus on Healthcare ... 2007 at 1:30 p.m. ET at the Millennium ... Therapeutics, Vicus Therapeutics is a privately-held, biopharmaceutical ...
... Dec. 3 Signalife, Inc.,(Amex: SGN ) ... Congress on,Cardiac Pacing and Electrophysiology to be held ... Dr. Muricio Arruda, who has been testing,Signalife,s wireless ... the Cleveland Clinic Heart Center, will,present a prototoype ...
Cached Biology Technology:BioMarin and IGAN Biosciences to Collaborate on Development of an Enzyme Therapy to Treat IgA Nephropathy, a Rare and Life-Threatening Kidney Disease 2BioMarin and IGAN Biosciences to Collaborate on Development of an Enzyme Therapy to Treat IgA Nephropathy, a Rare and Life-Threatening Kidney Disease 3BioMarin and IGAN Biosciences to Collaborate on Development of an Enzyme Therapy to Treat IgA Nephropathy, a Rare and Life-Threatening Kidney Disease 4Signalife Presence at XIII World Congress on Cardiac Pacing and Electrophysiology 2Signalife Presence at XIII World Congress on Cardiac Pacing and Electrophysiology 3
(Date:7/31/2014)... Since Alexandre Edmond Becquerel first discovered the photovoltaic effect ... harness the power of sunlight for its own purposes. ... 2014 issue of the FASEB Journal ... exploiting the power of sunlight by focusing on a ... conserved throughout evolution. This conservationor persistence over time and ...
(Date:7/31/2014)... Professor of Clinical Surgery at LSU Health Sciences Center ... team of plastic and reconstructive surgeons who report a ... select patients for a specific surgical migraine treatment technique. ... surgery to decompress the nerves that trigger migraines experienced ... The study, which confirms the benefit of surgical treatment ...
(Date:7/31/2014)... 31, 2014 Biometrics industry sees ... smart technologies; companies turn towards digital currency: NXT-ID, Inc. ... Amazon.com Inc. (NASDAQ: AMZN ), Facebook Inc. ... GOOG ) and Microsoft Corporation (NASDAQ: MSFT) ... the growing m-commerce market, announces a video featuring its ...
Breaking Biology News(10 mins):Scientists shine bright new light on how living things capture energy from the sun 2Surgeons report significant migraine relief from cosmetic eyelid surgery technique 2Smart Technology Consumer's Interest in Mobile Payment Products Grows - Company Secures Deal with Major Airline to Display Advertisements in Flight for its Next Generation Smart Wallet 2Smart Technology Consumer's Interest in Mobile Payment Products Grows - Company Secures Deal with Major Airline to Display Advertisements in Flight for its Next Generation Smart Wallet 3Smart Technology Consumer's Interest in Mobile Payment Products Grows - Company Secures Deal with Major Airline to Display Advertisements in Flight for its Next Generation Smart Wallet 4Smart Technology Consumer's Interest in Mobile Payment Products Grows - Company Secures Deal with Major Airline to Display Advertisements in Flight for its Next Generation Smart Wallet 5Smart Technology Consumer's Interest in Mobile Payment Products Grows - Company Secures Deal with Major Airline to Display Advertisements in Flight for its Next Generation Smart Wallet 6
... for overcoming sleep deprivation. Sam Ridgway from the US Navy ... half of their brains to sleep while the other half ... able to remain continually vigilant for sounds for days on ... San Diego and Tel Aviv wonder whether the dolphins, unrelenting ...
... the first time, experts have compiled a comprehensive overview ... for the treatment of several cancers. , Personalizing Cancer ... of results of therapeutic regimens across a broad range ... Journal of Nuclear Medicine is a unique reference tool ...
... 2009 As people become more educated, studies have demonstrated ... calories but higher in nutrients. They also pay more. In ... Journal of the American Dietetic Association , researchers from ... costs of a sample of 164 adults in the Seattle, ...
Cached Biology News:Dolphins maintain round-the-clock visual vigilance 2Publication sets guidelines across cancer therapies: Ensuring the best in patient management 2People of higher socioeconomic status choose better diets -- but pay more per calorie 2
The Wellwash 4 Mk 2 microplate washer combines flexibility, simplicity and ease of use. This reliable microplate washer meets the exacting standards of today's ELISA assay requirements....
... MLF1 Interacting Protein/PBIP1 (phospho T78) ( ... Antigen: Synthetic ... 73-83 of Human MLF1 Interacting Protein ... 359815 Swiss ...
... Nuclease is a genetically engineered endonuclease. This ... and RNA while having no proteolytic activity. ... of conditions and possesses an exceptionally high ... acids from recombinant proteins, its use enables ...
... save space and organize gloves, safety ... They are the perfect benchtop storage ... labs, processing and manufacturing. Clear static-dissipative ... particles they attract. Many other sizes ...
Biology Products: